These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing. Muller PY Adv Drug Deliv Rev; 2011 Jun; 63(7):511-7. PubMed ID: 21034787 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of adverse drug reactions to biologics. Clarke JB Handb Exp Pharmacol; 2010; (196):453-74. PubMed ID: 20020272 [TBL] [Abstract][Full Text] [Related]
6. Applying physiological and biochemical concepts to optimize biological drug development. Lowe PJ Clin Pharmacol Ther; 2010 Apr; 87(4):492-6. PubMed ID: 20147897 [TBL] [Abstract][Full Text] [Related]
7. Biopharmaceuticals in China. Hu X; Ma Q; Zhang S Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435 [TBL] [Abstract][Full Text] [Related]
8. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. Tamilvanan S; Raja NL; Sa B; Basu SK J Drug Target; 2010 Aug; 18(7):489-98. PubMed ID: 20192653 [TBL] [Abstract][Full Text] [Related]
9. FDA perspective on specifications for biotechnology products--from IND to PLA. Murano G Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677 [TBL] [Abstract][Full Text] [Related]
10. Design of clinical trials for therapeutic cancer vaccines development. Mackiewicz J; Mackiewicz A Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869 [TBL] [Abstract][Full Text] [Related]
11. Antibodies and genetically engineered related molecules: production and purification. Roque AC; Lowe CR; Taipa MA Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864 [TBL] [Abstract][Full Text] [Related]
15. First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Nada A; Somberg J Am J Ther; 2007; 14(6):594-604. PubMed ID: 18090886 [TBL] [Abstract][Full Text] [Related]
16. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138 [TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
18. Overcoming obstacles to monoclonal antibody product development and approval. Stein KE Trends Biotechnol; 1997 Mar; 15(3):88-90. PubMed ID: 9080714 [TBL] [Abstract][Full Text] [Related]
19. Hazard identification and risk assessment for biologics targeting the immune system. Weir AB J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852 [TBL] [Abstract][Full Text] [Related]
20. A brief survey of first-in-human studies. Wexler D; Bertelsen KM J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]